Journal of gastroenterology · 2025
Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maesaka Kazuki, Hikita Hayato, Tahata Yuki, Nishioka Chinatsu, Kai Machiko, Shirai Kumiko, Murai Kazuhiro, Makino Yuki, Saito Yoshinobu, Kodama Takahiro, Ohkawa Kazuyoshi, Miyazaki Masanori, Nozaki Yasutoshi, Yakushijin Takayuki, Sakamori Ryotaro, Tatsumi Nobuyuki, Matsumoto Kengo, Ishida Hisashi, Iio Sadaharu, Nawa Takatoshi, Kakita Naruyasu, Nakahara Masanori, Hosui Atsushi, Yoshida Yuichi, Usui Takeo, Imanaka Kazuho, Doi Yoshinori, Sakakibara Mitsuru, Takehara Tetsuo
Аннотация
BACKGROUND: Lenvatinib is widely used in hepatocellular carcinoma (HCC), but its efficacy following atezolizumab plus bevacizumab remains unclear. This study compared the therapeutic impact of lenvatinib administered after immunotherapy, following its use as a first-line systemic therapy.
METHODS: This retrospective study analyzed patients with unresectable HCC who received lenvatinib either after atezolizumab plus bevacizumab as second-line therapy or as first-line therapy. Propensity score matching (PSM) was applied to balance baseline characteristics. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared.
RESULTS: Following PSM, 63 matched pairs were analyzed. The "After Atezo + Beva" group had larger and more advanced intrahepatic tumors, but PSM balanced the groups' baseline characteristics. Based on mRECIST, the objective response rate and disease control rate were 41.1% and 80.4% in the "After Atezo + Beva" group, and 49.2% and 76.3% in the first-line group. Based on RECIST version 1.1, these were 25.0% and 80.4% vs. 28.8% and 76.3%, respectively. Median PFS was 4.5 vs. 5.2 months (p = 0.233) and median OS was 14.3 vs. 16.0 months (p = 0.769). Grades ≥ 3 AEs occurred more frequently in the "After Atezo + Beva" group (74.9% vs. 50.8%, p = 0.006), with grades ≥ 3 proteinuria in 31.7% vs. 14.3% (p = 0.020) and grades ≥ 3 fatigue in 12.7% vs. 1.6% (p = 0.033).
CONCLUSIONS: Lenvatinib demonstrated comparable efficacy whether used following atezolizumab plus bevacizumab or as first-line therapy in unresectable HCC. These findings support its clinical utility in the post-immune checkpoint inhibitor setting, with attention to AE management.
METHODS: This retrospective study analyzed patients with unresectable HCC who received lenvatinib either after atezolizumab plus bevacizumab as second-line therapy or as first-line therapy. Propensity score matching (PSM) was applied to balance baseline characteristics. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were compared.
RESULTS: Following PSM, 63 matched pairs were analyzed. The "After Atezo + Beva" group had larger and more advanced intrahepatic tumors, but PSM balanced the groups' baseline characteristics. Based on mRECIST, the objective response rate and disease control rate were 41.1% and 80.4% in the "After Atezo + Beva" group, and 49.2% and 76.3% in the first-line group. Based on RECIST version 1.1, these were 25.0% and 80.4% vs. 28.8% and 76.3%, respectively. Median PFS was 4.5 vs. 5.2 months (p = 0.233) and median OS was 14.3 vs. 16.0 months (p = 0.769). Grades ≥ 3 AEs occurred more frequently in the "After Atezo + Beva" group (74.9% vs. 50.8%, p = 0.006), with grades ≥ 3 proteinuria in 31.7% vs. 14.3% (p = 0.020) and grades ≥ 3 fatigue in 12.7% vs. 1.6% (p = 0.033).
CONCLUSIONS: Lenvatinib demonstrated comparable efficacy whether used following atezolizumab plus bevacizumab or as first-line therapy in unresectable HCC. These findings support its clinical utility in the post-immune checkpoint inhibitor setting, with attention to AE management.